TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02585869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcabene 150 mg
Description: Blinded capsules and tablets, 150 mg, once daily, 84 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcabene 300 mg
Description: Blinded capsules and tablets, 300 mg, once daily, 84 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcabene 600 mg
Description: Blinded capsules and tablets, 600 mg, once daily, 84 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcabene 900 mg
Description: Blinded capsules and tablets, 900 mg, once daily, 84 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Blinded capsule and tablets, once daily, 84 days
Study: NCT04268355

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training for Primary Care
Description: MTPC is a referral-based, insurance-reimbursable 8-week program delivered as group psychotherapy by Patient-Centered Medical Home-integrated behavioral clinicians or as an 8-week primary care group visit delivered by a primary care provider. MTPC groups are 2 hours for 8 weeks with a 7-hour weekend day of silent practice. MTPC emphasizes mindfulness-oriented skills for self-regulation, self-management of chronic illness, and health behavior change. All participants complete an action plan during Week 7. Participants are called every two weeks for the first eight weeks for 5-10 minute engagement calls which focus helping participants cultivate a relationship with study staff, giving participants a place to ask questions, and supporting participants in completing study visits.
Study: NCT01879293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03149536

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacogenetic test
Description: To develop a pharmacogenetic prediction test

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacogenetic test
Description: To develop a pharmacogenetic prediction test

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacogenetic test
Description: To develop a pharmacogenetic prediction test

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacogenetic test
Description: To develop a pharmacogenetic prediction test

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacogenetic test
Description: To develop a pharmacogenetic prediction test

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacogenetic test
Description: To develop a pharmacogenetic prediction test
Study: NCT01710462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole + Domperidone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantozol®
Study: NCT03880513

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular status and quality of life
Description: Psychosocial and cardiovascular evaluation includes medical history, physical examination, laboratory tests, analysis of endothelial function, 24h blood pressure profile, Holter ECG, transthoracic echocardiography, cardiac MRI, and quality of life assessment

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular status and quality of life
Description: Psychosocial and cardiovascular evaluation includes medical history, physical examination, laboratory tests, analysis of endothelial function, 24h blood pressure profile, Holter ECG, transthoracic echocardiography, cardiac MRI, and quality of life assessment
Study: NCT01685879

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rice
Description: Rice portion containing 50 g total carbohydrate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rice
Description: Rice portion that provides 50 g total carbohydrate.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rice
Description: Rice portion that provides 50 g total carbohydrate.
Study: NCT00550589

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: performed on punch biopsy specimens collected at baseline, after cycle 1, and 6 weeks after treatment discontinuation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: punch biopsy collected at baseline, after cycle 1, and 6 weeks after treatment discontinuation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: histopathologic examination
Description: Evaluated at baseline and 6 weeks after treatment discontinuation
Study: NCT04101214

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Dry needling into spastic muscle

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham dry Needling
Description: Sham dry needling into spastic muscle
Study: NCT05229276

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sternum Guard
Description: The intervention being assessed is a surgical drape used as a cover of sternal bones and the neighboring structures exposed during median sternotomy named Sternum Guard.~Sternum guard® is a single use, sterile surgical drape with modified cellulose designed specifically to reduce the risk of surgical site infection (SSI).~It is made of 4 parts, the main part is in contact with the retractors and the sternum edge. It is made of carboxymethylated cellulose (CMC) spunlace which makes direct contact with the sternum edges. It contributes to blood absorption, to decreasing of pH environment, and to haemostatic action through a physical effect (compression); another part was made from hydrophilic spunbond (swabs) allowing blood absorption, comfort and protection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bone Wax
Description: patients in this group were given Bone Wax as the hemostatic material during sternotomy. Midline sternotomy with an oscillating saw was conducted after standard aseptic surgical techniques. Bone wax was applied to both spongiosa surfaces of resected sternal bones until bleeding had ceased.
Study: NCT04601753

Intervention type: DRUG
Intervention: Oral Semaglutide
Description: Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
Study: NCT00943839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study: NCT02837224

Intervention type: DEVICE
Intervention: The Situate Detection System
Description: The Situate Detection System for locating surgical sponges
Study: NCT01716897

Intervention type: DRUG
Group type: OTHER
Intervention: E2609

Intervention type: DRUG
Group type: OTHER
Intervention: E2609

Intervention type: DRUG
Group type: OTHER
Intervention: E2609
Study: NCT04361955

Intervention type: OTHER
Group type: OTHER
Intervention: EMG
Description: recordings of muscle electrical activity during nerve stimulation using EMG

Intervention type: OTHER
Group type: OTHER
Intervention: EMG
Description: recordings of muscle electrical activity during nerve stimulation using EMG
Study: NCT01685879

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Glucose Beverage
Description: Glucose beverage that provides 50 g total carbohydrate.
Study: NCT03194477

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile-enhanced Engagement Intervention
Description: Mobile phone based enhanced case management intervention for HIV positive \& HIV negative young Black men who have sex with men.
Study: NCT04361955

Intervention type: OTHER
Group type: OTHER
Intervention: EEG
Description: recordings of brain activity using EEG

Intervention type: OTHER
Group type: OTHER
Intervention: EEG
Description: recordings of brain activity using EEG
Study: NCT06245148

Intervention type: OTHER
Intervention: Observation
Description: Observation

Intervention type: OTHER
Intervention: Observation
Description: Observation
Study: NCT00770029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (Xeomin) (20 Units)
Description: The treatment will be administered only once at day 0 at five injection sites in the glabellar area. The total dose of 20 Units IncobotulinumtoxinA (Xeomin) is reconstituted in a total injection volume of 0.5 mL that is to be injected to the five sites in equal aliquots of 0.1 mL.
Study: NCT00706316

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EBV-Specific CTLs and CD45 Mab
Description: One time infusion (IV) at one of the following dose levels:~Dose level I: 5 x 107 cells/m2~Dose level II: 1 x 108 cells/m2~Dose level III: 2 x 108 cells/m2
Study: NCT01558934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lofexidine HCl
Description: Lofexidine HCl 0.2 mg tablets titrated in ascending doses of 0.2 mg QID (e.g. Day 1 0.2 mg QID, Day 2 0.4 QID, etc)as described in the treatment arm.
Study: NCT02841124

Intervention type: OTHER
Group type: OTHER
Intervention: interviews
Description: face-to-face interviews with the referent oncologist (or hematologist) and his patient (conducted by a physician and a psychologist respectively) as well as interviews with other partners involved in the situation (care staff and relatives)
Study: NCT00770029

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The treatment will be administered only once at day 0 at five injection sites in the glabellar area. Volume of Placebo equivalent to IncobotulinumtoxinA (Xeomin).
Study: NCT04945889

Intervention type: DIAGNOSTIC_TEST
Intervention: Quick Sequential Organ Failure Assessment (qSOFA)
Description: Clinical bedside tool that evaluates three vital parameters, scoring one point each if altered: respiratory rate (RR) ≥22 breaths/minute, systolic blood pressure (SBP) ≤100 mmHg and altered mental status (defined in our study as either Glasgow Coma Scale (GCS) score \<15 or any worsening in the Italian Oriented, Disoriented, Agitated, Sleepy scale). A qSOFA score ≥2 points is considered indicative of sepsis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Modified Early Warning Score (MEWS)
Description: Clinical bedside tool that evaluates five vital parameters, with multiple scoring according to alteration: respiratory rate (0-3 points), heart rate (0-3 points), systolic blood pressure (0-3 points), body temperature (0-2 points), mental status (0-3 points, evaluated using the Alert, Verbal, Pain, Unresponsive - AVPU scale). A MEWS score ≥5 points is considered indicative of an acute condition at risk of sudden clinical deterioration.

Intervention type: DIAGNOSTIC_TEST
Intervention: National Early Warning Score (NEWS)
Description: Clinical bedside tool that evaluates seven parameters, with multiple scoring according to alteration: respiratory rate (0-3 points), oxygen saturation (0-3 points), need for any supplemental oxygen (0-2 points), body temperature (0-3 points), heart rate (0-3 points), systolic blood pressure (0-3 points), mental status (0-3 points, evaluated using the Alert, Verbal, Pain, Unresponsive - AVPU scale). A NEWS score ≥7 points is considered indicative of an acute condition at risk of sudden clinical deterioration.
Study: NCT02121951

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local Anesthetic infiltration
Description: Lignocaine infiltration through the nephrostomy track

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum block
Description: A linear 12-MHz ultrasound probe will be placed in the anterior axillary line to visualize the typical triple abdominal layers. Then, the probe will be placed in the midaxillary line and at this point the layers of abdominal layers starte to taper. The probe will be placed in the posterior axillary line, sonoanatomy will show first the transversus abdominis disappearing then the internal oblique and external oblique forming aponeurosis and appearance of QL will be noticed. At the posterior border of the quadratus lumborum muscle and outside the fascia, Touhe needle will be inserted in plane and confirmed its position by injecting saline. Under ultrasound (US) guidance, local anesthetic mixure will be deposited separating the fascia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MAC
Description: Incremental doses are given to the targed sedation and analgesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAC
Description: Incremental doses are given to the targed sedation and analgesia
Study: NCT02746432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyper insulinemic euglycemic clamp
Description: After obtaining a baseline preoperative lab set blood glucose value, 2 U/kg bolus of insulin (Human regular insulin) to be administered IV followed by an infusion of 2 U/ kg/min.fiver - Ten minutes after starting the insulin infusion, and when the blood glucose is \<6.1 mmol /L (110 mg /dL). an Infusion of dextrose 20% supplemented with pottasium phosphate (30 mmol/L ) to be administered. In the operating room, blood glucose levels were measured every 5-15 minutes, and the dextrose infusion rate was adjusted to maintain arterial glycemia between 3.5 and 6.1 mmol/L (63-110 mg/dL). timed intra operative lab assessment to be obtained.
Study: NCT00818168

Intervention type: BIOLOGICAL
Intervention: Infliximab
Description: Dosage and infusion intervals were employed in~accordance to the Summary of Product Characteristics (SmPC)
Study: NCT00535756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Creon
Description: 3 capsules Creon with 25000 lipase units per main meal (3 main meals) plus 2 capsules per snack (2-3 snacks)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04094688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Given IV

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Given PO

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03745911

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Paclitaxel and TAK-228
Description: Treatment with TAK-228 oral (D2, 3 and 4 of each week) and paclitaxel (D1 of each week) on Days 1, 8 and 15 for each 28-days cycle until disease progression or unacceptable toxicity. If paclitaxel is stopped, TAK-228 may be continued
Study: NCT02914418

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation using iTBS Paradigm
Description: TMS is a non-invasive, painless method of stimulating the central and peripheral nervous system. ITBS is a form of TMS which is delivered for \~200sec and can promote changes in neural activity.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation using iTBS Paradigm
Description: TMS is a non-invasive, painless method of stimulating the central and peripheral nervous system. ITBS is a form of TMS which is delivered for \~200sec and can promote changes in neural activity.
Study: NCT02365727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liposomal bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study: NCT03988244

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeartLight X3
Description: Pulmonary vein isolation
Study: NCT03635528

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 1
Description: EMO-114

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 1
Description: EMO-114

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 1
Description: EMO-114

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 1
Description: EMO-114

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 1
Description: EMO-114

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 1
Description: EMO-114

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 1
Description: EMO-114

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 1
Description: EMO-114

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 1
Description: EMO-114

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 1
Description: EMO-114

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 1
Description: EMO-114

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 1
Description: EMO-114

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 1
Description: EMO-114

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 1
Description: EMO-114

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 2
Description: EMO-116

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 2
Description: EMO-116
Study: NCT01584713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adipose-derived stem cells without expanded
Description: Administration will be intralesional injection of cells suspension. They will be placed into fistula walls
Study: NCT02969785

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: G1: exercises for lumbar stabilization
Description: Specific exercises for lumbar stabilization. The Group 1 (G1) will perform therapy with specific exercises for lumbar stabilization whith the Swiss ball as a therapeutic resource, including warming; stretching of hamstrings, paraspinals, trapezes; phasic perineal exercise; tonic perineal exercise; pelvic lumbar synergism; trunk mobility; mobility of the shoulder girdle; balance; and slow pelvic balance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: G2: back strengthening exercises
Description: Specific back exercises. The Group 2 (G2) will perform therapy including back strengthing exercise on a Roman chair machine to perform flexion and extension of trunk with load progressive training.
Study: NCT02810782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenobarbital
Description: Phenobarbital per os

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorpromazine
Description: Chlorpromazine per os

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine per os
Study: NCT02989974

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KY LEADS Survivorship Care
Description: Survivor: Survivor questionnaire 1 at enrollment; KY LEADS Survivorship Care Program; survivor questionnaire 2 one week after program completion; survivor questionnaire 3 six months after enrollment.~Caregiver: Caregiver questionnaire 1 at enrollment;KY LEADS Survivorship Care Program; caregiver questionnaire 2 one week after program completion; caregiver questionnaire 3 six months after enrollment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KY LEADS Survivorship Care
Description: Survivor: Survivor questionnaire 1 at enrollment; KY LEADS Survivorship Care Program; survivor questionnaire 2 one week after program completion; survivor questionnaire 3 six months after enrollment.~Caregiver: Caregiver questionnaire 1 at enrollment;KY LEADS Survivorship Care Program; caregiver questionnaire 2 one week after program completion; caregiver questionnaire 3 six months after enrollment
Study: NCT00598091

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Description: 1000mg/m2, Days 1, 8, 15

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dasatinib
Description: 50mg, PO, QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Description: 1000mg/m2, days 1, 8, 15

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dasatinib
Description: 50mg, PO, BID